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Abstract Transdermal technology is currently approved
in the US for the administration of more than 20 medica-
tions. This current review describes the clinical research
pertaining to the use of a methylphenidate patch in the
treatment of attention-deficit hyperactivity disorder
(ADHD) in children and adolescents. PubMed searches
were conducted using the search term ‘methylphenidate
transdermal system’, and were limited to clinical trials. No
limits were set for dates of publication. A total of 21
citations were identified. Studies evaluating the safety and
efficacy of the methylphenidate transdermal system (MTS)
in children and adolescents were included in this review.
Additional studies were identified from bibliographies and
the ‘Related Citations’ section of PubMed searches. The
MTS delivers a range of methylphenidate doses using a
drug-in-adhesive matrix patch. According to current
labeling, the patch should be applied to the hip once daily
for a maximum of 9 h. Serum methylphenidate levels
increase over wear time, with mean time to maximum
concentration (tmax) reached between 8 and 10 h for a 9-h
wear time, and the elimination half-life for methylpheni-
date is 3–4 h after patch removal. In clinical trials, ADHD
symptoms were measured using the ADHD Rating Scale,
Version IV, and several parent-, teacher-, and patient-rated
scales. Treatment effects show statistically significant dif-
ferences from baseline symptom scores starting at the first
evaluation, 2 h after the patch is applied, with significant
benefit lasting up to 12 h with a 9-h wear time. Adverse
events with the MTS are similar to those seen with other
formulations of methylphenidate, with the exception of
skin-related reactions at the site of application, which were
generally mild to moderate in severity. The incidence of
contact allergic dermatitis with MTS is\1 %. Statistically
significant improvements in health-related quality of life
and medication satisfaction were also observed with the
MTS compared with placebo, and after switching from oral
extended-release (ER) methylphenidate. Transdermal drug
delivery is an effective and safe means of administering
methylphenidate for patients with ADHD.
1 Overview of Transdermal Technology
Currently, there are more than 20 medications available in
the US that use generic and branded transdermal systems
[1]. These include patch products for smoking cessation,
antihypertensives, pain relievers, anti-nausea medications,
and hormone therapies. There is a growing trend of using
transdermal delivery for agents that act in the central ner-
vous system, such as cholinesterase inhibitors for dementia,
monoamine oxidase inhibitors for depression, dopamine
agonists for Parkinson’s disease [2] and restless leg syn-
drome [2], as well as clonidine for hypertension [3] and
methylphenidate for attention-deficit hyperactivity disorder
(ADHD) [4].
1.1 Potential Advantages of Transdermal Delivery
In an effort to improve adherence to treatment, individu-
alizing therapy is a growing trend in the management of
chronic conditions. The development of transdermal sys-
tems has facilitated individualizing the duration of therapy
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for patients because a patch can be removed, stopping the
delivery of medication, unlike orally administered medi-
cations which remain in the system once ingested. Trans-
dermal absorption minimizes first-pass metabolism, hepatic
side-effects, the attendant potential for drug–drug interac-
tions, as well as the risk of gastrointestinal irritation may be
reduced [1]. Steady absorption of drug through the skin
may provide more consistent drug exposure during dosing
and might avoid serum drug peaks and troughs [5]. This
reduction of peaks and troughs may, in turn, decrease the
incidence of adverse effects [1]. Long-acting (LA) trans-
dermal patches often require less frequent dosing, which
may also help improve adherence to treatment [6, 7].
Although there are few data regarding children and
adolescents, patch technology does appear to improve
adherence to treatment in a range of patient populations [6–
8]. In one trial of a contraceptive patch, excellent adher-
ence and no pregnancies among adolescent patients were
reported [8]. In a survey of 1,470 patients with asthma or
chronic obstructive pulmonary disease, 84 % of patients
reported that they used their tulobuterol patch as pre-
scribed, whereas the rate was 31–64 % for individuals
using an inhaler [9]. Patients cited once-daily dosing as a
key factor in their adherence. A study of 649 patients with
mild-to-moderate dementia from Alzheimer’s disease
found that patients who were prescribed patches had higher
rates of adherence than those receiving oral medications
[7]. A survey of 1,059 caregivers showed that more than
70 % preferred using a rivastigmine patch rather than
capsules for the treatment of Alzheimer’s patients in their
care [10]. Caregivers preferred the dosing schedule, ease of
use with the patch over oral administration, and reported
greater overall satisfaction and less interference with daily
life when using the patch.
1.2 Potential Limitations of Transdermal Delivery
Of course, these possible benefits must be weighed against
potential disadvantages. For some drugs, transdermal
delivery is associated with a delayed onset of action
compared with oral and parenteral administration [1].
Absorption of drug can be compromised if the patch does
not properly remain in contact with the skin. Some patients
develop irritant or allergic contact dermatitis leading to the
discontinuation of treatment [1].
Skin irritation may result from exposure to the drug
being administered or the structural components of the
patch. A review of transdermal delivery systems for seven
different drugs showed that between 20 % and 50 % of
users reported skin irritation that was usually mild in
severity [11]. Irritant contact dermatitis is the most com-
mon type of dermal reaction seen at patch application sites,
and it is an inflammatory response localized to the site and
characterized by erythema, but it may also be itchy and
edematous. However, irritant contact dermatitis usually
resolves without treatment after removal of the irritant
[11]. Skin irritation may lead to occlusion of sweat ducts,
resulting in formation of itchy, red papulomas that are also
self-resolving—usually within 24 h of patch removal.
Removal of the patch itself may cause transient erythema
alone or may be accompanied by flare and edema (triple
response of Lewis) [11].
1.3 Types of Patches
Transdermal administration is used to deliver drugs locally
(e.g. anti-inflammatory agents for pain) or systemically via
the circulation. Passive transdermal drug delivery systems
may be categorized as either reservoir or matrix designs. In
the former, the drug is stored in one or more reservoirs
located between the backing of the patch and a membrane
that is engineered to control the rate of diffusion into the
skin [1]. In the matrix design, the drug is embedded either
in the adhesive (drug-in-adhesive patches), or in a layer of
matrix material between the adhesive layer and the back-
ing. The total amount of drug delivered is related to the rate
of drug delivery from the matrix, as well as being pro-
portional to the surface area of the patch that is in contact
with the skin and the duration of application.
With both passive designs, once the patch is applied to
the skin, a diffusion gradient is established, and the drug
moves into the stratum corneum, the outer layer of the skin
(Fig. 1). Transit through the stratum corneum is carried out
by diffusion through intercellular lipids [12]; this is the
rate-limiting step in passive transdermal drug delivery [1].
Therefore, drugs that are suitable for passive patch tech-
nology have a small molecular mass (\500 Da) and are
lipophilic [1, 13]. These drugs must be chemically stable
during patch storage and during transdermal diffusion
when the patch is on the patient’s body. Patches are typi-
cally designed such that residual drug concentrations in the
patch are low when they are applied for the recommended
duration of wear time.
1.4 Transdermal Drug Delivery Systems
in Development
No transdermal delivery systems for larger molecules and
peptides are currently approved by the US FDA. Active
delivery systems for such drugs are the subject of ongoing
research. One approach, iontophoresis, uses administration
of a low electrical current to actively drive diffusion of
charged molecules across the stratum corneum without the
need to increase skin permeability. Ultrasound (sonopho-
resis) can be used to increase permeability of the stratum
corneum. Although the mechanism by which sonophoresis
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works is not completely understood, it is thought to
increase permeability through a combination of cavitation
(formation of gas-filled cavities), mechanical and thermal
effects, and induction of convection transport [14]. Other
methods such as chemical agents that facilitate drug transit
through the stratum corneum, microneedle, thermal abla-
tion, and microdermabrasion are in development but are
not yet approved for administration of larger and more
highly charged molecules [12].
2 Transdermal Methylphenidate in Attention-Deficit
Hyperactivity Disorder (ADHD)
2.1 ADHD
In the US, about 7 % of children aged 4–17 years (about 4
million) carry a diagnosis of ADHD in the community [15].
Compared with the general population, individuals with
ADHD carry a higher risk of learning disabilities, mood
disorders, anxiety, and disruptive behavioral disorders [16,
17]. As children mature, the resulting impairments may
persist, resulting in higher rates of accidents, lower high-
school graduation rates, difficulty in the workplace, and
poorer psychosocial functioning [18].
All FDA-approved ADHD medication dosage forms
are oral, except for one methylphenidate patch. Current
guidelines recommend stimulant medications, such as
dextroamphetamine, d- and d,l-methylphenidate, or mixed
salts of amphetamine, as first-line treatments for children
[18, 19]. These agents act as dopamine and norepineph-
rine reuptake inhibitors, and likely target frontostria-
tal neurocircuits [20]. The response rates are similar
for short- and long-acting formulations (approximately
80 %), as are the reported effect sizes (0.91) [21, 22].
Methylphenidate and amphetamines share the same side-
effect profiles, the most common of which are delayed
sleep onset, decreased appetite, abdominal pain, headache,
rebound irritability, motor and vocal tics, and jitteriness
[16].
Adherence to treatment is a challenge with most chronic
disorders, and ADHD is no exception. Discontinuation and
non-adherence among patients who are prescribed ADHD
medication vary with the definition of adherence and the
method used to measure. Analyses of large claims dat-
abases show that, on average, patients discontinue ADHD
medication less than 1 year after the first prescription [23].
The need for multiple doses, inflexibility of medication
duration, and inability to swallow tablets or capsules are
additional considerations when treating patients with
ADHD. A variety of formulations have been developed to
address these issues. Liquid formulations and capsules
whose contents can be sprinkled on food are available for
persons who have difficulty swallowing. Both stimulants
and non-stimulant medications for ADHD are available in





























Fig. 1 Passive patch
technology. Once the patch is
applied to the skin, a diffusion
gradient is established, and the
drug moves into the stratum
corneum
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2.2 Overview of the Methylphenidate Transdermal
System (MTS)
At this time, the methylphenidate transdermal system
(MTS) is the only transdermal treatment approved by the
FDA for the treatment of ADHD in the US. Efficacy has
only been established in children aged 6–12 years and
adolescents aged 13–17 years [4]. The MTS is a drug-in-
adhesive matrix patch containing a racemic mixture of d-
and l-enantiomers of methylphenidate. The methylpheni-
date dose delivered is dependent on the size of the patch,
the application site, and the wear time. Thus, a shorter wear
time results in a shorter duration of action. The current
design of the MTS is based, in part, on the pharmacokinetic
studies showing that when the patch is worn for 9 h, peak
plasma concentrations of methylphenidate are reached at
about 8 h after multiple patch applications, and the elimi-
nation half-life is 3–4 h [4]. The package insert recom-
mends application to the hip area approximately 2 h before
effect is needed, and the MTS patch can be worn for up to
9 h. Four patch sizes are available (12.5, 18.75, 25, and
37.5 cm2), which deliver 10-, 15-, 20-, and 30-mg doses,
respectively, based on a 9-h wear time [4]. The patch can
be removed prior to 9 h if a shorter duration of dosing is
desired [24].
2.3 Comparative Pharmacokinetics of MTS Compared
with Oral Methylphenidate Formulations
The differences between MTS and immediate- and exten-
ded-release oral methylphenidate formulations reside in
their pharmacokinetic profiles. The pharmacokinetic profile
of MTS was evaluated in a phase II, randomized, placebo-
controlled laboratory classroom study involving 80 chil-
dren aged 6–12 years who were treated for ADHD [25].
Doses were titrated to methylphenidate 10, 15, 20, or
30 mg delivered over a 9-h MTS wear time. Systemic
exposure was proportional to dose, and the effectiveness
was observed between the first observation at 2 h after
patch application and 12 h after patch application. These
observations were expanded in a second pharmacokinetic
study—conducted in 35 children aged 6–12 years and 36
adolescents aged 12–16 years—that compared the phar-
macokinetic profiles of d- and l-methylphenidate enantio-
mers following administration of single, multiple fixed, and
escalating doses of MTS or osmotic release oral system
(OROS) methylphenidate 18 mg once daily [5].
The pharmacokinetic profiles of methylphenidate fol-
lowing single and multiple MTS and OROS doses are
shown in Fig. 2. Circulating levels of d-methylphenidate
were higher in children than for adolescents for all dos-
ing regimens tested [5]. For the single-dose determina-
tions, all patients received MTS 10 mg/9 h or OROS
methylphenidate 18 mg/day. Blood samples were taken
before dosing and at 1, 2, 4, 6, 8, 9, 10, 12, 14, 24, and 30 h
post-dosing. Following the single dose, the concentration
of d-methylphenidate was not measureable at the 1- or 2-h
sampling times, suggesting that absorption of methylphe-
nidate with MTS administration is delayed by about 2 h. In
contrast, serum concentrations of methylphenidate
increased rapidly after administration of a single OROS
methylphenidate dose. The mean time to maximum con-
centration (tmax) for d-methylphenidate was 10.0 h (range
8.00–12.0) in children and 10.0 h (range 6.00–12.0) in
adolescents with MTS, whereas the tmax following a single
OROS methylphenidate dose was 6.02 h (range 4–10) in
children and 8.00 h (range 1–10) in adolescents [5]. The
same dosing regimens were extended for 10 days for the
multiple fixed-dose analyses. Accumulation (defined as the
maximum concentration [Cmax] at steady state over the
Cmax after a single dose) of d-methylphenidate was 34 % in
children and 57 % in adolescents after 7 days of MTS
10 mg/9 h per day, and 13 % in children and 19 % in
adolescents following 7 days of OROS methylphenidate
18 mg/day [5]. Consistent with these accumulation data,
serum methylphenidate was measurable at the 1 and 2 h
sampling times after multiple dosing. The concentration-
time curves suggest that lower doses of methylphenidate
administered by a transdermal patch compared with OROS
methylphenidate could achieve the same plasma levels of
d-methylphenidate. Trough concentrations at steady state
(between days 7 and 14 of escalated dosing) were similar
between MTS and OROS methylphenidate when compared
across corresponding doses in the same age group. As
shown in Fig. 2, with MTS administration, serum levels of
d-methylphenidate increased and did not decline during the
9-h wear time following multiple doses. As expected with
OROS methylphenidate administration, serum d-methyl-
phenidate levels increased rapidly over the first 1–2 h, and
continued to increase, reaching a mean tmax at 6 h (range
4–10) after single and 8 h (range 4.00–10.0) after multiple
fixed doses in children 6–12 years of ages. The mean tmax
in adolescents (13–17 years) was 8 h (range 1–10) after
1 day of OROS methylphenidate 18 mg/day dosing, and
was similar after 7 days [5].
Another difference of potential clinical importance
between the MTS and other methylphenidate formulations
is exposure to l-methylphenidate, which appears to be
higher with the MTS relative to other formulations of
methylphenidate following single or multiple doses. Cir-
culating levels of l-methylphenidate are negligible after
single or multiple doses in patients treated with oral
methylphenidate and, as a result, the effects of this enan-
tiomer have not been well characterized. The clinical
implications of l-methylphenidate absorption with the
MTS, if any, remain to be elucidated [5].
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The application site can affect the bioavailability and
pharmacokinetic profile of drugs administered through the
skin. A comparison of two sites found that application of
MTS to the hip resulted in a significantly greater Cmax than
application to the scapula (33.8 ± 10.2 vs. 26.2 ± 11.2 ng/
mL, p = 0.01 hip vs. scapula) in boys and girls (aged
6–12 years) during a 16-h wear time [26]. The area under
the curve from 0 to 16 h (AUC0–16) was also greater with
hip placement, although the tmax was only slightly longer
with hip placement.
2.4 Phase II Efficacy Trials
Several studies were conducted to determine the appro-
priate dosing range and wear times for MTS in children. In
a phase II study, doses of MTS worn for 9 h daily were
optimized over a 5-week period. In this placebo-controlled,
crossover study (N = 80) conducted in a laboratory
classroom, most children (63 %) were know to be
responsive to stimulants, while the rest were treatment
naive. Compared with placebo transdermal system (PTS),
MTS treatment was associated with significantly lower
scores (3.2 ± 0.58 vs. 8.0 ± 0.58; p \ 0.0001) on the
primary efficacy measure (mean Swanson, Kotkin, Agler,
M-Flynn, and Pelham Rating Scale deportment [SKAMP
D] scores) over both laboratory classroom days at post-
dose hours 2 through 9. The effect size, Cohen’s d, for
MTS based on this primary efficacy measure is 0.93 [27].
Response rates were not reported. The difference in
behavioral and academic measures between MTS treatment
and PTS was statistically significant by the first timepoint
and 2 h after application, and remained improved 12 h
after application (3 h after removal). During the dose
optimization phase prior to randomization, 13 participants
withdrew from the study—seven due to adverse events
(AEs), one due to lack of efficacy, three withdrew consent,
and two were lost to follow-up [27]. The incidence of any
AE during the laboratory classroom period was 30 % with
MTS and 23 % with PTS [27]. The most frequent AEs with
MTS were decreased appetite, anorexia, headache,
insomnia, and upper abdominal pain. These results sug-
gested that a 9-h wear time was safe and well tolerated, and
a b
c d
Fig. 2 Mean plasma concentration-time profiles from day 1 to 31 for
d-methylphenidate after single and multiple doses of MTS and OROS
MPH in children aged 6–12 years (a, c) and adolescents aged
13–17 years (b, d) in the pharmacokinetic population. MTS 10 mg
(day 1) indicates a single dose; MTS 10 mg (day 10), multiple fixed
dose for 7 days; MTS 10 mg (day 31), multiple fixed dose for
28 days; MTS 30 mg, multiple escalating dose for 28 days (10, 15,
20, and 30 mg for 7 days each); OROS MPH 18 mg (day 1), single
dose; OROS MPH 18 mg (day 10), multiple fixed dose for 7 days;
OROS MPH 54 mg (day 31), multiple escalating dose for 28 days
(18, 27, 36, and 54 mg for 7 days each). MTS methylphenidate
transdermal system, OROS MPH osmotic-release oral system meth-
ylphenidate. Reprinted with permission from Pierce et al. [25]
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provided a broad window of efficacy with once-daily
dosing.
Two studies assessed various dose and time combina-
tions. In the first study, both dose and onset of action were
assessed in 36 children aged 6–13 years [28]. Doses ranged
from 0.45 mg/h to 1.8 mg/h, and wear times were at least
12 h per day. Participants were enrolled in a summer
treatment program. This study showed that based on
counselor, teacher, and parent ratings of behavior, there
was little or no benefit to increasing the dose above
0.45 mg/h in the structured setting. To determine the best
time to apply the patch prior to the need for symptom
control, parents were instructed to apply patches either 60
or 120 min before the start of the program activities.
Although time of application had no overall effect on daily
behavior, fewer behavioral problems arose during the first
hour of activities when the patches were administered
120 min rather than 60 min before class. AEs were typical
of those reported with methylphenidate, and the incidence
of AEs increased at higher doses. The incidence of parent-
reported insomnia was 22 % across all doses at these long
wear-times [28]. Another study of similar design was
conducted in 27 children [29]. In this trial, MTS doses
(patch sizes 12.5, 25, or 37.5 cm2) were varied randomly
over 24 days and worn for 8.5 h daily (unless moderate or
severe side effects occurred, in which case patches were
removed earlier). Behavior modification therapy was added
on alternate weeks. This study showed that similar ADHD
Rating Scale (ADHD-RS) scores could be achieved with
lower MTS doses when patients received supplemental
behavioral therapy [29]. As was observed in the other study
by Pelham et al., the incidence of AEs appeared to be dose
related. Two patients who were randomized to receive the
highest dose on the first day withdrew because of AEs (tics,
buccal lingual movements, and insomnia) at that dose. One
child withdrew from study treatment because of a dermal
reaction [29].
Before-school symptom control and functioning were
assessed as secondary outcomes in a randomized, placebo-
controlled, crossover designed study of 30 children with
ADHD to determine the time of onset of ADHD symptom
improvement following MTS application [30]. Parents
were instructed to apply the MTS between 6.00 am and
7.00 am, and before school; evaluations were based on
behavior between 6.00 am and 9.00 am. Reductions in
baseline scores for the ADHD-AM-RS (ADHD-RS evalu-
ated between 6.00 am and 9.00 am) were greater during
MTS treatment (67 % reduction vs. baseline) than during
placebo transdermal treatment (25 % reduction vs. base-
line; p = 0.003 for MTS vs. placebo). Scores on the
before-school functioning questionnaire, which investi-
gated activities such as listening to parents and teachers,
following directions, and hygiene, were also significantly
better with MTS. Patterns and frequency of AEs were
similar to those observed in other MTS trials [30].
2.4.1 Variable Wear Times
Unlike oral formulations, the MTS patch wear time can be
varied. This provides patients and caretakers with the
ability to modify the duration of treatment effect, and can
be used to minimize side effects by limiting treatment to
the times when effective symptom reduction is desired. The
safety and efficacy of using variable wear times (4 and 6 h)
was evaluated in a phase IIb study of 117 children aged
6–12 years in an analog classroom setting over a period of
8 weeks [24]. Behavioral ratings on the SKAMP deport-
ment scores returned to baseline levels between 2 and 4 h
after patch removal for both wear times. For the 4-h wear
time, Permanent Product Measure of Performance
(PERMP) scores declined rapidly between 2 and 6 h after
patch removal. A slower decline in PERMP scores was
observed after the 6-h wear time. Most AEs were mild to
moderate, and no unexpected events were reported. The
most frequent AEs were decreased appetite (28 %), head-
ache (21 %), insomnia (20 %), and abdominal pain (12 %)
[24].
2.4.2 Switching from Oral Methylphenidate
To determine the safety and efficacy of switching from an
oral methylphenidate formulation to the MTS, the effects
of an abrupt switch from oral methylphenidate ER (Ritalin
LA, Concerta, or Metadate controlled delivery [CD]) were
assessed in a 4-week, open-label study [31]. MTS dosing
was based on the previous daily oral dose of methylphe-
nidate ER. Those previously receiving Concerta 18 mg and
Ritalin LA or Metadate CD 10 or 20 mg were switched to
MTS 10 mg/9 h; Concerta 27 mg and Ritalin LA or
Metadate CD 30 mg were switched to MTS 15 mg/9 h;
Concerta 36 mg and Ritalin LA or Metadate CD 40 mg
were switched to MTS 20 mg/9 h; and Concerta 54 mg and
Ritalin LA or Metadate CD 50 mg were switched to MTS
30 mg/h. Patients remained on their initial MTS transition
dose for 1 week and then entered a 2-week dose-adjust-
ment period. An increase or decrease in dose was permitted
based on tolerability, and Clinical Global Impression-
Severity (CGI-S) scores were assessed by investigators.
After the final dose adjustment visit at the end of week 3,
no further changes in dose were permitted. No dose
adjustment was required for 58 % of 164 children after the
switch. Overall, 4 % (6/164) required a smaller patch size
(lower dose) and 38 % (63/164) required a larger patch size
(higher dose). Mean ADHD-RS total scores were signifi-
cantly improved over baseline at study end (9.9 ± 7.47 vs.
14.1 ± 7.48; p \ 0.0001) [31]. Most patients (68–83 %)
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across doses had skin reaction scores of 0 (no reaction) or 1
(minimal erythema). Four participants withdrew because of
skin reactions. The most frequently reported AEs were
headache, decreased appetite, insomnia, and abdominal
pain of mild to moderate intensity [31]. These results
suggest that switching to MTS from oral methylphenidate
is generally well tolerated and that patients may achieve
better symptom control with the adjusted doses of MTS
when compared with previously administered fixed oral
doses of methylphenidate ER.
2.4.3 Patch adhesion
Patch adhesion was evaluated in two studies. In a labora-
tory classroom study (N = 80 randomized), [90 % patch
surface was found to have remained adherent in 86 % of
the children after 9 h of wear [27]. Patch adhesion over
12 h of wear time was evaluated during an 8-day summer
program, which included participation in swimming and
other physical activities. Among the 36 participants during
the 8-day period, 18 patches came off and another 18
required taping [27].
3 MTS Clinical Trials (Phases III and IV)
3.1 Pediatric Patients (Aged 6–12 Years)
3.1.1 Efficacy
In 2006, the MTS received an indication for use in pedi-
atric patients with ADHD based on results showing effi-
cacy with 9-h patch wear times in the classroom and
community settings (Table 1) [32–36]. Findling et al. [32]
conducted a 7-week, randomized, double-blind, placebo-
controlled, naturalistic study assessing MTS in 270 pedi-
atric patients with ADHD. Treatment with OROS methyl-
phenidate was used as an active control. The primary
efficacy endpoint was the change from baseline ADHD-
RS, Version IV (ADHD-RS-IV) total score at study end.
The Conners’ Teachers Rating Scale-Revised (CTRS-R)
was the main secondary efficacy measure. Parents evalu-
ated their children’s response to treatment using the Con-
ners’ Parents Rating Scale-Revised (CPRS-R). The
difference in change from baseline ADHD-RS-IV for MTS
versus a placebo patch was statistically significant on the
primary analysis (-24.2 with MTS vs. -10.3 with placebo;
p \ 0.0001). Change from baseline CTRS-R and CPRS-R
also showed statistically significant differences between
MTS and placebo. The difference in change from baseline
ADHD-RS-IV for OROS methylphenidate versus a
placebo patch was statistically significant on the primary
analysis (-21.6 with OROS methylphenidate vs. -10.3
with placebo; p \ 0.0001). All measures with OROS
methylphenidate were also statistically significantly better
than with placebo treatment [32].
The most commonly reported AEs were decreased
appetite, nausea, vomiting, and insomnia in all treatment
groups, and most AEs were of mild-to-moderate intensity.
Percentages of children with any AE were 76 % with MTS,
69 % with OROS methylphenidate, and 56 % with PTS.
Discontinuation rates due to AEs were 7, 2, and 1 % in the
MTS, OROS methylphenidate, and PTS groups, respec-
tively [32]. The MTS patch was well tolerated, with 7.1 %
of patients discontinuing study treatment because of AEs
compared with 2.2 % in the OROS methylphenidate group
and 1.2 % in the placebo group. Four patients on MTS
reported edema, and two patients on MTS discontinued
treatment related to application-site reactions. Mild skin
irritation occurred in the MTS group in the Findling et al.
2008 study [32], where 77 % of the 98 patients reported no
evidence (51.5 %) or minimal evidence (25.5 %) of
irritation.
3.1.2 Long-Term Safety and Tolerability
A total of 327 patients were enrolled in a 1-year, open-label
safety extension of four trials. Most (81 %) reported at
least one AE [33]. Of the AEs, 98 % were mild or mod-
erate in severity and approximately 40 % were considered
related to the study treatment. The discontinuation rate due
to AEs was 9 %. The majority of those who withdrew
(7 %) did so because of dermal reactions.
Long-term growth data were also collected for 127
children for up to 37 months during the open-label
extension study [35]. Comparisons were made with long-
term growth data from 61 children who were excluded at
baseline. Treatment with MTS was associated with small
but significant deficits in growth parameters, including
height (0.68 cm less per year), weight gain (1.3 kg less
per year), and body mass index (BMI; 0.49 units less per
year). There was an early and pronounced reduction in
growth rates from 0 to 12 months followed by a period
from 12 to 36 months in which the reduction in growth
rates was less significant. Deficits in weight gain and BMI
increases were more apparent than deficits in growth. The
overall findings suggest that although MTS treatment has
a small negative impact on growth, these effects attenuate
over time. Patients who were above average in height,
weight, or BMI at baseline were more likely to experi-
ence significant growth deficits in all parameters com-
pared with average or small patients at baseline. Prior
stimulant use, total time treated, and doses of ADHD
medications were predictive of growth deficits with
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respect to expected changes in body weight and BMI, but
not height [35].
3.1.3 Sleep Quality
The impact of MTS treatment on sleep was analyzed as a
secondary endpoint in an 8-week pivotal trial [34]. The
Children’s Sleep Habits Questionnaire (CSHQ) was
administered at baseline and at all subsequent visits for the
duration of the 8-week study. There was no statistically
significant difference in the frequency or severity of sleep
disturbance among treatment groups. The dose of methyl-
phenidate administered with the patch or with OROS
methylphenidate was not significantly correlated with
either the frequency or severity of sleep behavior problems
[34]. Similar results were found in a second open-label
study involving 26 patients with ADHD and a history of
difficulty sleeping [37]. MTS wear times ranged from
9–12 h. Patients were randomized to one of four sequences
of 9-, 10-, 11-, and 12-h wear times. Sleep latency and total
sleep time were not negatively affected by the duration of
wear time.
3.1.4 Dermal Responses
Dermal reactions were characterized in 305 children
aged 6–12 years with ADHD who were enrolled in an
open-label, dose-optimization study [36]. After a 4-week
dose-titration period, patients continued to wear the MTS
at the optimized dose of 10, 15, 20, or 30 mg for 9 h per
day on alternating hips for an additional 3 weeks.
Application-site evaluations were conducted at weeks 0,
1, 2, 3, 4, 5, and 8. The current application site and the
site from the previous day were scored using a 7-point
dermal response score (DRS), where 0 is no irritation
and 7 is strong reaction spreading beyond the test site.
At the scheduled visits, evaluation of the current appli-
cation site showed that 46.9 % of patients had DRS
scores of B1. Another 49 % had DRS scores of 2, 2.0 %
had DRS scores of 3, and 1.0 % (four patients) had DRS
scores of 4. No DRS scores [4 were reported at any
time during the trial. In an assessment of the previous
day’s application sites, 82 % of patients had DRS scores
of B1. DRS scores did not tend to increase with
increasing MTS doses. More than 90 % of patients
reported either no discomfort or mild discomfort at the
current or previous day’s application site. Three of the
four patients with a DRS score of 4 were successfully
switched to oral methylphenidate. The fourth individual
withdrew from the study and subsequently had a mild
patch test response to methylphenidate, indicating aller-
gic contact sensitization [36].
3.2 Adolescent Patients (Aged 13–17 Years)
3.2.1 Efficacy and Safety
Similar benefit and tolerability with MTS has been
observed in adolescents diagnosed with ADHD (Table 2)
[38, 39]. Safety and efficacy were evaluated in a 7-week,
double-blind, randomized, placebo-controlled, community-
based study [38]. Patients were randomized to treatment
with MTS or a placebo patch (PTS). A total of 215 patients
were included in a 5-week dose-optimization period fol-
lowed by 2 weeks on a stable dose. At study endpoint, the
difference from baseline ADHD-RS-IV score was signifi-
cantly greater in the MTS group than the PTS group (dif-
ference -9.96 [95 % CI -13.39 to -6.53]; p \ 0.001).
Results on the CPRS also showed significant improvement
with MTS compared with the PTS at study end. Frequently
reported AEs were typical of those observed in clinical
trials of stimulants. Dermal reactions were generally mild;
however, 3 of 215 patients discontinued treatment as a
result of skin irritation [38].
3.2.2 Long-Term Safety and Tolerability
Long-term safety and tolerability of MTS treatment in 163
adolescents (mean age 14.5 ± 1.2 years) were assessed in
a 6-month, open-label extension study [39]. As was
observed during the 7-week study, treatment-emergent AEs
were typical for patients receiving stimulants and were
generally mild to moderate in severity. The most frequently
reported AEs were decreased appetite (15 %) and headache
(12 %). A total of 54 % of patients completed the exten-
sion study, with 7 % (12 patients) discontinuing because of
AEs [39].
3.3 Quality of Life
Health-related quality of life assessed using the ADHD
Impact Module-Child (AIM-C), and medication satisfac-
tion measured with the Medication Satisfaction Survey
were secondary outcome measures in a variable wear-time
study in 128 children aged 6–12 years [40] (Table 3). After
a screening and washout period and 5-week dose titration
period using 9-h wear times, outcomes with 4- and 6-h
wear times were compared using a placebo-controlled,
double-blind, three-way crossover design. Pooled data
across MTS doses showed that both child and family
quality of life increased from baseline at the post-titration
visit (5 weeks) and at study end (8 weeks) [40]. Medica-
tion satisfaction was consistent at the 5- and 8-week visits,
with 92 and 89 % of parents reporting high satisfaction at
those respective timepoints.
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To understand the temporal relationship of ADHD
symptom relief, satisfaction with treatment, and family
health-related quality of life, a post hoc analysis of
these data was conducted [41]. Over the course of the
open-label dose-titration period, improvement in ADHD
symptoms, caregiver satisfaction with medication, and
child health-related quality of life improved at the
same time, suggesting that improvement in health-
related quality of life might coincide with symptom
amelioration.
Table 2 Summary of Phase III and IV MTS safety and efficacy trials in adolescents aged 13–17 years
Study Study design/ duration
(N)











LS mean difference for
MTS vs. PTS: -9.96
CPRS-R total score for
MTS vs. PTS: -13.48
CGI-I percentage very
































scores from study entry
to endpoint
\0.001 Majority ([99 %) were mild or
moderate in intensity, and the
most frequently reported TEAE





ADHD-RS-IV Attention-Deficit Hyperactivity Disorder Rating Scale, Version IV; CGI-I Clinical Global Impression-Improvement, CPRS-R Conners’
Parents Rating Scale-Revised, LS least squares, MTS methylphenidate transdermal system, PTS placebo transdermal system, TEAE treatment-emergent
adverse event
Table 3 Summary of health-related quality-of-life trials with MTS






Abruptly switched from a stable dose of





AIM-C child and family HRQL mean
scores were above the median possible
score at baseline and were further
improved at endpoint across all MTS
doses
93.8 % of caregivers indicated a high
level of satisfaction with their child’s




Subanalysis of a phase IIb
multicenter, randomized,
placebo-controlled, three-
way crossover study (115)
After 5-week dose optimization of MTS
for 9 h/day, MTS was worn for 4 or







Mean AIM-C child and family HRQL
scale scores improved from baseline to
endpoint across all MTS doses. The
magnitude of improvement increased
with time from baseline
Parents/LARs indicated a high level of
satisfaction with their child’s use of





Subanalysis of a phase IIb
multicenter, randomized,
placebo-controlled, three-
way crossover study (117)
After 5-week dose optimization of MTS
for 9 h/day, MTS was worn for 4 or







HRQL was not a delayed response to
improvement in symptoms
Children showed a uniform pattern of
improvement in HRQL that followed
symptom change; three distinct
patterns of change were found for
improvement in family HRQL
ADHD-RS Attention-Deficit Hyperactivity Disorder Rating Scale, AIM-C ADHD Impact Module-Child, LAR legally appointed representative,
MTS methylphenidate transdermal system, MPH ER methylphenidate extended-release, HRQL health-related quality of life
226 R. L. Findling, S. Dinh
The feasibility of switching to the MTS from an oral
agent was evaluated in a 4-week, open-label study
involving 164 children aged 6–12 years [31, 42]. Patients
were switched from a stable dose of one of three oral ER
methylphenidate formulations (Ritalin LA, Metadate CD,
Concerta) to the MTS using a dose-transition schedule
[42]. Patients remained on their initial MTS transition dose
for 1 week and then entered a 2-week dose-adjustment
period. An increase or decrease in dose was permitted
based on tolerability and CGI-S scores assessed by inves-
tigators. After the final dose-adjustment visit at the end of
week 3, no further changes in dose were permitted. Scores
on the AIM-C showed improvement in health-related
quality of life for patients and their families after the
switch. Approximately 94 % of parents and caregivers
reported a high level of satisfaction with the study treat-
ment on the MTS, suggesting that the switch did not sub-
stantially disrupt health-related quality of life [42]. These
findings are consistent with those of Arnold et al. [31] who
evaluated efficacy and tolerability in the same trial. In the
latter study, there was a significant improvement in
ADHD-RS total scores after 4 weeks of using MTS, with
good tolerability [31].
4 Conclusions
Passive transdermal delivery is a safe and effective means
of administering small lipophilic molecules that has been
found to improve adherence to therapy. Indicated for use in
children and adolescents with ADHD, the MTS offers
additional practical advantages such as once-daily dosing
and flexible wear times. In addition to being clinically
effective in reducing symptoms of ADHD, with the
exception of generally minor dermal AEs, the MTS has a
side-effect profile similar to that of other stimulants.
Moreover, patients and caregivers report a significant
improvement in patient and family quality of life and
overall satisfaction with medication with MTS use.
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